I don’t have a target price on ABT because it’s one of the stocks I intend to hold indefinitely (barring a fundamental change in the business).
In calculating year-over-year results, currency should have a positive effect during most, or all, of 2017. (Since ABT generates about 2/3 of its sales ex-US, currency effects are more consequential than for most S&P 500 companies.)
The recent sell-off relating to the FDA warning is a pretty good entry point, IMO, but ABT isn’t really a stock for traders because the volatility is low.
Market Data 
Markets 
AI
